Research
How to read and evaluate peptide research: trial phases, study quality, and common pitfalls.
45 articlesFOXO4-DRI and Peptide Senolytics: What the Animal Research on "Zombie Cell" Clearance Shows
FOXO4-DRI is sold online as a 'senolytic' peptide for clearing aged cells. The research behind it is real, and it's entirely in mice.
Read the guide → 🔬 ResearchWhy Most Peptide Drugs Can't Be Taken as a Pill: Oral Bioavailability and the Enzyme-Degradation Problem
Most peptide drugs are injected rather than swallowed. Here's the basic biochemistry behind why, and how drugs like oral semaglutide manage to get around it.
Read the guide → 🔬 ResearchWhat Is a Dose-Ranging (Phase 2b) Trial? Why GLP-1 Developers Test Multiple Doses
Nearly every GLP-1 obesity drug headline cites a Phase 2b dose-ranging trial. Here's what that trial design actually does, and why it matters before a drug reaches Phase 3.
Read the guide → 🔬 ResearchSemaglutide and Alzheimer's: What the EVOKE and EVOKE+ Trials Found
Novo Nordisk tested oral semaglutide in early Alzheimer's disease in two large Phase 3 trials. Here's what EVOKE and EVOKE+ actually found, and what it means for GLP-1 drugs and brain health.
Read the guide → 🔬 ResearchTopline Results vs. Peer-Reviewed Publication: Why the Gap Between a Press Release and a Published Study Matters
What it means when a drug company announces 'topline' trial results, how that differs from peer-reviewed publication, and why the distinction matters for reading peptide and GLP-1 drug news.
Read the guide → 🔬 ResearchWhat Is a Surrogate Endpoint? Why Regulators and Drugmakers Debate Using Them
Surrogate endpoints let clinical trials measure a stand-in marker instead of a true outcome like a heart attack or death. Here's how they work in peptide and GLP-1 research, and why they're controversial.
Read the guide → 🔬 ResearchWhat Is GIP? The Second Incretin Hormone Behind Tirzepatide's Dual-Agonist Design
GIP is the lesser-known incretin hormone paired with GLP-1 in tirzepatide. Here's what it does, and why both GIP agonism and antagonism are being pursued for weight loss.
Read the guide → 🔬 ResearchPlacebo Run-In Periods in Obesity Drug Trials: Why Some Studies Screen Out Placebo Responders First
Some obesity and GLP-1 drug trials use a placebo run-in period before randomization. Here's what that design choice does, and why it's worth checking for when reading trial results.
Read the guide → 🔬 ResearchWhat Orphan Drug Designation Means for Peptide Drug Development
Many FDA-approved peptide drugs, from teduglutide to setmelanotide, reached the market through the Orphan Drug Act. Here's what the designation actually grants, and what it doesn't.
Read the guide → 🔬 ResearchNon-Inferiority Trials Explained: Why "Not Worse Than" Is a High Bar in Peptide Drug Research
Many recent peptide and GLP-1 trials are designed to show a new drug isn't meaningfully worse than an existing one, not that it's better. Here's how non-inferiority trials work, and why the margin matters.
Read the guide → 🔬 ResearchPlacebo-Adjusted vs. Observed Weight Loss: Why Trial Percentages Can Be Misleading
The weight-loss percentage in a drug’s headline often isn’t the number that applies to an average patient. Here’s the difference between observed, placebo-adjusted, and completer-only results.
Read the guide → 🔬 ResearchHow Peptide Drugs Are Manufactured: Solid-Phase Synthesis vs. Recombinant DNA Production
The two main ways peptide drugs get made, chemical solid-phase synthesis and recombinant DNA production, and why many modern GLP-1 drugs actually combine elements of both.
Read the guide → 🔬 ResearchAppetite-Regulating Hormones Beyond GLP-1: Leptin, Ghrelin, PYY, and CCK Explained
GLP-1 is only one signal in a much larger hormonal network that controls hunger and fullness. Here's what leptin, ghrelin, PYY, and CCK actually do, and where real drugs already target them.
Read the guide → 🔬 ResearchHow AI Is Changing Peptide Drug Discovery
How pharmaceutical companies are using machine learning and generative AI to design new peptide drug candidates, and what still requires traditional clinical trials.
Read the guide → 🔬 ResearchWhat Is EASD? How Major Diabetes and Obesity Conferences Shape Peptide Drug News
What the European Association for the Study of Diabetes annual meeting is, why so much peptide drug trial data gets released there, and how to read conference-presented results.
Read the guide → 🔬 ResearchWhat an FDA Complete Response Letter Means, and Which Peptide Drugs Have Gotten One
What an FDA Complete Response Letter actually means for a drug application, using Novo Nordisk's once-weekly insulin icodec as a real peptide-drug example, and how it differs from a rejection.
Read the guide → 🔬 ResearchCan Antibodies Preserve Muscle During GLP-1 Weight Loss? What the Early Trial Data Shows
A look at the research behind pairing GLP-1 drugs like semaglutide with myostatin- and activin-targeting antibodies, an experimental approach aimed at preserving lean muscle mass during rapid weight loss.
Read the guide → 🔬 ResearchGLP-1 Medications and the Gut Microbiome: What the Research Shows
What animal and early human studies show about how GLP-1 receptor agonists affect gut bacteria, and how much of that research still hasn't moved beyond early stages.
Read the guide → 🔬 ResearchImmunogenicity in Peptide Drugs: Why Some Trigger Antibody Responses and Others Don't
Why the immune system sometimes recognizes therapeutic peptides as foreign, and how researchers test for and manage that risk.
Read the guide → 🔬 ResearchGDF15 Explained: The Next Wave of Appetite-Regulating Peptides Beyond GLP-1
Why researchers are targeting GDF15 as an obesity pathway distinct from GLP-1, and why nausea has been the biggest obstacle.
Read more → 🔬 ResearchReal-World Evidence vs. Randomized Controlled Trials: What Each Can (and Can't) Tell Us
How real-world evidence studies differ from randomized controlled trials, what each research design is good at, and why the distinction matters when reading claims about peptide therapies.
Read the guide → 🔬 ResearchHow Peptide Half-Life Gets Extended: Fatty Acid Conjugation, PEGylation, and Fc-Fusion Explained
The three main chemistry techniques, fatty acid conjugation, PEGylation, and Fc-fusion, that turn short-lived natural peptides into once-weekly or once-monthly drugs.
Read the guide → 🔬 ResearchOpen-Label vs. Blinded Trials: Why Study Design Shapes How You Read the Results
Whether a trial is blinded or open-label changes how much confidence to place in its results, and several major recent peptide-drug head-to-head trials have been open-label by necessity.
Read the guide → 🔬 ResearchWhat a Biologics License Application Is, and Why It Matters for Peptide Drugs
Some peptide drugs are approved through a New Drug Application, others through a Biologics License Application. Here's the difference and why it matters for retatrutide and other next-generation peptides.
Read the guide → 🔬 ResearchFast Track, Breakthrough Therapy, and Priority Review: What FDA Designations Mean for Peptide Drugs
FDA designations like Fast Track and Breakthrough Therapy speed up development or review. None of them mean a drug is approved, or will be.
Read the guide → 🔬 ResearchWhat an FDA Advisory Committee Vote Actually Means (and Doesn't)
A plain-language explainer of what FDA advisory committees do, why their votes are nonbinding, and how to interpret advisory-panel news headlines correctly.
Read the guide → 🔬 ResearchClinical Trial Phases Explained: What Phase 1, 2, and 3 Actually Mean
A plain-language breakdown of what happens in Phase 1, 2, and 3 clinical trials, and why each phase matters.
Read the guide → 🔬 ResearchComparing Study Quality Across Popular Peptide Therapies
A side-by-side framework for comparing the research quality behind different popular peptides discussed on this site.
Read the guide → 🔬 ResearchConflicts of Interest in Peptide Research: What to Watch For
How financial and commercial conflicts of interest can influence peptide research, and how to spot them.
Read the guide → 🔬 ResearchDose-Response Studies: Why "More" Isn't Always Better in Research
What dose-response research shows about peptide effects, and why higher doses aren't automatically more effective or safer.
Read the guide → 🔬 ResearchHow Researchers Measure Growth Hormone Secretagogue Effects
The specific lab measurements researchers use to evaluate growth hormone secretagogue peptides, and what those measurements do and don't tell you.
Read the guide → 🔬 ResearchHow Researchers Study Injury Repair Peptides Like BPC-157 and TB-500
The typical methods researchers use to study injury repair peptides in animal and cell models, and their limitations.
Read the guide → 🔬 ResearchHow to Read a Peptide Study on PubMed Without a Science Degree
A practical guide to reading and evaluating a peptide research study on PubMed without specialized scientific training.
Read the guide → 🔬 ResearchHuman Evidence vs. Animal Evidence: Why the Distinction Matters for BPC-157
Why BPC-157's impressive animal research doesn't reliably predict effects, dosing, or safety in humans.
Read the guide → 🔬 ResearchMeta-Analyses Explained: How Researchers Combine Study Results
What a meta-analysis is, how researchers combine results across multiple studies, and why they carry particular weight.
Read the guide → 🔬 ResearchPlacebo-Controlled Trials: Why They're the Gold Standard
Why placebo-controlled trial design is considered the gold standard for evaluating whether a treatment actually works.
Read the guide → 🔬 ResearchReplication in Science: Why One Study Is Never the Final Word
Why scientific replication matters, the replication crisis in context, and how to weigh a single study versus a body of research.
Read the guide → 🔬 ResearchSemaglutide's Clinical Trial Record: STEP and SELECT Explained
An overview of the STEP and SELECT clinical trial programs behind semaglutide's approvals for weight management and cardiovascular risk.
Read the guide → 🔬 ResearchThe Evidence Gap Between Popular Peptides and FDA-Approved Drugs
A direct comparison of the evidence base behind FDA-approved peptide drugs versus popular research-chemical peptides.
Read the guide → 🔬 ResearchThe Role of Animal Models in Early-Stage Peptide Research
Why animal research is a necessary part of drug development, and its specific strengths and limitations.
Read the guide → 🔬 ResearchTirzepatide's Pivotal Trials: What the SURMOUNT and SURPASS Data Showed
An overview of the SURMOUNT and SURPASS clinical trial programs behind tirzepatide's FDA approval.
Read the guide → 🔬 ResearchWhat "Statistically Significant" Actually Means in a Clinical Trial
A plain-language explanation of statistical significance, p-values, and what they do and don't tell you about a study result.
Read the guide → 🔬 ResearchWhat Peer Review Does (and Doesn't) Guarantee About a Study
What passing peer review actually means for a study's reliability, and its real limitations.
Read the guide → 🔬 ResearchWhat a Systematic Review Adds That a Single Study Can't
How a systematic review differs from a regular literature review, and why its methodology matters for reliability.
Read the guide → 🔬 ResearchWhy Case Reports and Anecdotes Aren't the Same as Clinical Evidence
Why individual case reports and personal anecdotes, while sometimes useful, don't substitute for controlled clinical evidence.
Read the guide → 🔬 ResearchWhy Sample Size Matters in Peptide Research
Why small studies are more vulnerable to misleading results, and how to weigh sample size when evaluating peptide research.
Read the guide →